{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2"],"submitter":["Bays HE"],"pubmed_abstract":["<h4>Background</h4>This \"Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022\" is intended to provide clinicians an overview of Food and Drug Administration (FDA) approved anti-obesity medications and investigational anti-obesity agents in development.<h4>Methods</h4>The scientific information for this Clinical Practice Statement (CPS) is based upon published scientific citations, clinical perspectives of OMA authors, and peer review by the Obesity Medicine Association leadership.<h4>Results</h4>This CPS describes pharmacokinetic principles applicable to those with obesity, and discusses the efficacy and safety of anti-obesity medications [e.g., phentermine, semaglutide, liraglutide, phentermine/topiramate, naltrexone/bupropi"],"journal":["Obesity pillars"],"pagination":["100018"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10662004"],"repository":["biostudies-literature"],"pubmed_title":["Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022."],"pmcid":["PMC10662004"],"pubmed_authors":["Fitch A","Burridge K","Christensen S","Bays HE","Tondt J"],"additional_accession":[]},"is_claimable":false,"name":"Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.","description":"<h4>Background</h4>This \"Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022\" is intended to provide clinicians an overview of Food and Drug Administration (FDA) approved anti-obesity medications and investigational anti-obesity agents in development.<h4>Methods</h4>The scientific information for this Clinical Practice Statement (CPS) is based upon published scientific citations, clinical perspectives of OMA authors, and peer review by the Obesity Medicine Association leadership.<h4>Results</h4>This CPS describes pharmacokinetic principles applicable to those with obesity, and discusses the efficacy and safety of anti-obesity medications [e.g., phentermine, semaglutide, liraglutide, phentermine/topiramate, naltrexone/bupropi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-05-29T09:24:06.273Z","creation":"2025-02-19T04:22:52.401Z"},"accession":"S-EPMC10662004","cross_references":{"pubmed":["37990711"],"doi":["10.1016/j.obpill.2022.100018"]}}